This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...

A decision is expected in the fourth quarter of 2025.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...